Phosphoinositide 3-kinase (PI 3-K) is implicated in a wide array of biological and pathophysiological responses, including tumorigenesis, invasion and metastasis, therefore specific inhibitors of the kinase may prove useful in cancer therapy. We propose that specific inositol polyphosphates have the potential to antagonize the activation of PI 3-K pathways by competing with the binding of PtdIns(3,4,5)P 3 to pleckstrin homology (PH) domains. Here we show that Ins(1,3,4,5,6)P 5 inhibits the serine phosphorylation and the kinase activity of Akt/PKB. As a consequence of this inhibition, Ins(1,3,4,5,6)P 5 induces apoptosis in ovarian, lung and breast cancer cells. Overexpression of constitutively active Akt protects SKBR-3 cells from Ins(1,3,4,5,6)P 5 -induced apoptosis. Furthermore, Ins(1,3,4,5,6)P 5 enhances the proapoptotic effect of cisplatin and etoposide in ovarian and lung cancer cells, respectively. These results support a role for Ins(1,3,4,5,6)P 5 as a specific inhibitor of the PI 3-K/Akt signalling pathway, that may sensitize cancer cells to the action of commonly used anticancer drugs.
Introduction
Considerable evidence indicates that phosphoinositide 3-kinase (PI 3-K) signalling plays a central role in the development of several features of cancer (Chang et al., 1997; Khwaja et al., 1997; Vanhaesebroeck et al., 1997; Fruman et al., 1998; Rameh and Cantley, 1999) . It has been shown that PIK3Ca, the gene encoding the p110a catalytic subunit of PI 3-K, is present in increased copy number in several ovarian cancer cell lines (Shayesteh et al., 1999) and an elevated PI 3-K activity has been found in lung cancer cell lines (Moore et al., 1998) . In addition, it is well established that the tumour suppressor protein, phosphatase and tensin homolog (PTEN), whose gene is deleted or mutated in a wide variety of human cancers, possesses a 3-phosphoinositide-phosphatase activity (Maehama and Dixon, 1998) . The lipid products of PI 3-K act via specific interactions with some lipid-recognition/binding domains of which the pleckstrin homology (PH) domain is now the largest represented (Haslam et al., 1993; Corvera and Czech, 1998; Leevers et al., 1999) . This well-recognized, multifunctional structural domain consists of some 100-120 amino acids that share a specific tertiary structure (Shaw, 1996; Ferguson, 1998, 2000) . The majority of PH domaincontaining proteins appear to have a functional requirement to be membrane-associated and several studies indicate that PH domains function as membrane adapters or tethers, linking their host proteins to the membrane surface where the proteins are required for their function (Lemmon et al., 1997) . Indeed, many PI 3-K downstream effectors are activated through the binding of their PH domains to lipid products of PI 3-K on the plasma membrane and their subsequent translocation Maffucci and Falasca, 2001) . Thus, we propose that molecules able to bind specifically to the PH domains of downstream effectors of PI 3-K have the potential to antagonize the activation of these proteins by inhibiting their translocation to the plasma membrane or to any specific membrane compartment . The serine/threonine protein kinase B (PKB), also known as Akt, is one of the best-characterized PI 3-K downstream targets (Downward, 1998) . A crucial step in the activation of Akt is its translocation to the plasma membrane via interaction of its PH domain with 3 0 -phosphoinositides (Franke et al., 1997a; Frech et al., 1997; Klippel et al., 1997) . Once recruited to the plasma membrane, Akt can be phosphorylated on Thr-308 by the phosphoinositide-dependent kinase-1 (PDK-1) (Alessi et al., 1996; Banfic et al., 1998) and on Ser-473 by a still unknown kinase. PDK-1 itself is recruited to the plasma membrane via the interaction of its PH domain with 3 0 -phosphorylated phosphoinositides (Stokoe et al., 1997) . Several lines of evidence indicate that activation of Akt is both necessary and sufficient for survival since it regulates the downstream phosphorylation of further signalling proteins which, in turn, leads to the choice of cellular proliferation or apoptosis (Burgering and Coffer, 1995; Franke et al., 1997b; Kennedy et al., 1997) . In particular, it has been demonstrated that Akt promotes survival through the inactivation of caspase-9 and the activation of the transcription factor NF-kB (Baraud et al., 1999; Kane et al., 1999) . In addition it phosphorylates different components of the apoptotic machinery, such as BAD and forkhead transcription factor (FKHRL 1) (Cardone et al., 1998; Brunet et al., 1999) . Our attention is focused on the mechanisms of membrane targeting mediated by the lipid products of PI 3-K. An approach to inhibition of PI 3-K is through the disruption of the membrane localization of its targets by the use of their headgroup targetrecognition pattern, the inositol polyphosphates . Indeed, as different PH domains possess different binding affinities towards different inositol polyphosphates, this increases the possibility of specifically inhibiting a particular membrane-targeted protein (Kavran et al., 1998) , without interfering with other PI 3-K-mediated pathways. In combination with our recent work Razzini et al., 2000) we propose that inositol polyphosphates can act as specific antagonists of these functions.
The goal of this study is to investigate inositol polyphosphates as potential inhibitors of PI 3-K, as switch-off signal molecules, by competition with the localization of PH domain-containing proteins to the plasma membrane. Our results indicate that Ins(1,3,4,5,6)P 5 is able to inhibit Akt phosphorylation and kinase activity, leading to an induction of apoptosis in small cell lung cancer (SCLC-H69), ovarian cancer (SKOV3) and breast cancer (SKBR-3) cell lines. Overexpression of a constitutively active Akt reversed the Ins(1,3,4,5,6)P 5 -mediated effects, confirming that Akt is the target of Ins(1,3,4,5,6)P 5 action. Moreover, Ins(1,3,4,5,6)P 5 sensitizes breast, ovarian and lung cancer cell lines to anticancer drugs.
Results
Ins(1,3,4,5,6)P 5 induces apoptosis in cancer cell lines
We have recently found that specific inositol polyphosphates, namely Ins(1,4,5,6)P 4 and Ins(1,3,4,5,6)P 5 , inhibit cell growth and tumorigenicity in the human cancer cell lines SCLC-H69 and SKOV3 (Razzini et al., 2000) . To examine the effect of Ins(1,3,4,5,6)P 5 on tumour cell growth we measured cell apoptosis in SCLC-H69 and SKOV3 cells. Apoptosis was quantified with different methods, including cell morphology, acridine orange assay, Annexin V-binding assay, DNA fragmentation and 4 0 ,6-diamidino-2-phenyindole (DAPI) assay. As shown in Figure 1a , Ins(1,3,4,5,6)P 5 induced apoptosis, similar to etoposide, the most effective drug commonly used against SCLC-H69. SCLC-H69 control culture exhibited about 11% cells undergoing apoptosis, whereas Ins(1,3,4,5,6)P 5 clearly induced apoptosis reaching more than 40% at 100 mM. The effect of Ins(1,3,4,5,6)P 5 on cell apoptosis in SCLC-H69 cells was confirmed by DNA fragmentation assay ( Figure 1b) and Annexin V-binding assay ( Figure 1c) .
To assess the specificity of Ins(1,3,4,5,6)P 5 , we then evaluated the effects of different inositol polyphosphates on cell apoptosis in SCLC-H69 by acridine orange/ ethidium bromide assay. As shown in Figure 1d , Ins(1,3,4,5,6)P 5 was able to induce apoptosis whereas other inositol polyphosphates, such as Ins(1,4,5,6)P 4 , Ins(3,4,5,6)P 4 and inositol hexakisphosphate (InsP 6 ) have little or no effect. We next tested the effects of Ins(1,3,4,5,6)P 5 on cell apoptosis in SKOV3. Ins(1,3,4,5,6)P 5 induces apoptosis to the same extent as cisplatin ( Figure 2a ) and PI 3-K inhibitors LY294002 and wortmannin (not shown). SKOV3 control cells exhibited 9.071.5% cells undergoing apoptosis, whereas Ins(1,3,4,5,6)P 5 clearly induced apoptosis reaching 38.174.8% at 100 mM. These results were confirmed by using Annexin V-binding assay as shown in Figure 2b . Other inositol polyphosphates tested on SKOV3, such as Ins(1,4,5,6)P 4 , Ins(3,4,5,6)P 4 and InsP 6 have little or no effect on cell apoptosis (data not shown). Taken together these results indicate that Ins(1,3,4,5,6)P 5 specifically induces apoptosis in different cancer cell lines.
Ins(1,3,4,5,6)P 5 inhibits Akt phosphorylation and activity
We hypothesized that the Ins(1,3,4,5,6)P 5 effect occurs through inhibition of the PI 3-K signalling cascade by competing with PtdIns(3,4,5)P 3 binding to PH domains such as that of Akt. Taking into consideration that Akt might play a critical role in cell survival, we tested the effect of inositol polyphosphates on Akt phosphorylation in SKOV3 cells. As shown in Figure 3a , serine 473 Akt phosphorylation is inhibited by Ins(1,3,4,5,6)P 5 . On the contrary, neither Ins(3,4,5,6)P 4 nor Ins(1,4,5,6)P 4 (Figure 3a ) or InsP 6 (not shown) showed any significant effect (Figure 3a) .
We next determined the effect of inositol polyphosphates on Akt kinase activity in SCLC-H69 cells by using an in vitro kinase assay. Ins(1,3,4,5,6)P 5 inhibited Akt kinase activity (4373% inhibition at 50 mM) and it was more active than Ins(1,4,5,6)P 4 (2672.5% inhibition at 50 mM) (Figure 3b) . To confirm the effect of Ins(1,3,4,5,6)P 5 on Akt activation, Akt kinase activity was assessed by using a nonradioactive immunoprecipitation kinase assay to measure the phosphorylation of the downstream effector GSK3. This assay confirmed the inhibitory effect of Ins(1,3,4,5,6)P 5 but not of other inositol polyphosphates on GSK3 phosphorylation tested in SKOV3 (Figure 3c ) and SCLC-H69 cells (Figure 3d ).
Taken together these results indicate that Ins(1,3,4,5,6)P 5 can inhibit Akt activity and, as a consequence of this inhibition, it can block Aktdependent signalling pathways.
Ins(1,3,4,5,6)P 5 specifically inhibits the PI 3-K/Akt pathway It has been recently reported that different breast cancer cell lines show different levels of Akt activity (Clark et al., 2002) . In fact, some cell lines such as SKBR-3 have high levels of Akt activity, whereas others such as MCF-7 and MDA-MB-231 have low levels of Akt activity. Therefore, to confirm that Ins(1,3,4,5,6)P 5 can interfere with PI 3-K/Akt pathways, we tested the effect of Ins(1,3,4,5,6)P 5 on cell viability by using (473) was then assessed in Western blot analysis by using a specific anti-p-Ser(473) antibody. The total amount of Akt was also assessed by using an anti-Akt antibody. Blot is representative of three independent experiments. (b) SCLC-H69 cells were plated in six-well plates and treated with 50 mM of different inositol polyphosphates or 100 nM wortmannin for 30 min. Akt was immunoprecipitated and assayed using 'Akt1/ PKB alpha IP-Kinase' kit. Data represent the mean7s.e. of three independent experiments. (c) SKOV3 and (d) SCLC-H69 cells were incubated with 50 mM of the indicated inositol polyphosphates in serum-free DMEM for 2 h and Akt kinase activity was assessed using the 'Akt kinase assay' kit. Phosphorylation of GSK3 was assessed in Western blot analysis by using phospho-GSK3 a/b (Ser21/9) antibody. Densitometry analysis was carried out and phospho-GSK3 levels were normalized to the corresponding total amount of Akt. Blot is representative of two independent experiments. For SKOV3 cells (c) the densitometry analysis shown is mean7s.e.m. of four independent experiments Effect of inositol pentakisphosphate on apoptosis E Piccolo et al viability in SKBR-3 but neither MCF-7 nor MDA-MB-231 cells were affected. To explore whether Akt was involved in the Ins(1,3,4,5,6)P 5 -mediated effect on cell apoptosis, a myristoylated, constitutively active Akt (Myr-Akt) was transiently transfected into SKBR-3 cells and apoptosis was assessed by acridine orange/ethidium bromide staining. The expression levels were verified using an anti-Akt antibody (inset Figure 4b) . Overexpression of constitutively active Myr-Akt abrogated the effect of Ins(1,3,4,5,6)P 5 on cell apoptosis (Figure 4b ), confirming that Akt is the primary target of Ins(1,3,4,5,6)P 5 . Similar data were obtained by using a myc-tagged Myr-Akt (data not shown). In addition, overexpression of pKMyc-Myr-Akt in SKBR-3 cells prevented the Ins(1,3,4,5,6)P 5 -dependent inhibition of Akt phosphorylation (Figure 4c ). Transfection efficiency of the construct was assessed by confocal microscopy analysis (Figure 4c ). These data confirm a strict correlation between the Ins(1,3,4,5,6)P 5 -dependent apoptotic rate and the degree of inhibition of Akt signalling.
Ins(1,3,4,5,6)P 5 specifically inhibits PTEN À/À ES cell growth
To study the specificity of inositol polyphosphates as PtdIns(3,4,5)P 3 competitors, we performed a cell growth Figure 4 Ins(1,3,4,5,6)P 5 specifically inhibits the PI 3-K/Akt pathway. (a) MDA-MB-231, MCF-7 and SKBR-3 cells were seeded into 96-well microtiter plates and treated with 50 mM Ins(1,3,4,5,6)P 5 , 100 nM, wortmannin or 25 mM LY294002 for 48 h. Cell viability was assessed by MTT assay, measuring the absorption value at 570-690 nm. Data represent the mean7s.e. of three independent experiments performed in duplicate. (b) SKBR-3 cells were transiently transfected with cDNAs encoding a constitutively active Akt (pCis2-Myr-Akt) or empty vector (pCis2). Cells were then incubated with 50 mM Ins(1,3,4,5,6)P 5 for 24 h and apoptosis was assessed by acridine orange/ethidium bromide staining. Data represent the mean7s.e. of three independent experiments performed in duplicate. Expression of Myr-Akt was assessed in Western blot analysis by using an anti-Akt antibody (inset). (c) SKBR-3 cells were transiently transfected with cDNAs encoding a myc-tagged Myr-Akt (pKMyc-Myr-Akt) or empty vector (pKMyc). After 24 h, cells were incubated with 50 mM Ins(1,3,4,5,6)P 5 or 100 nM wortmannin for 2 h and phosphorylation of Akt at Ser(473) was assessed using a specific anti-p-Ser(473) antibody. Expression of pKMyc-Myr-Akt was assessed by confocal microscopy analysis by using an anti-myc antibody Effect of inositol pentakisphosphate on apoptosis E Piccolo et al assay in PTEN À/À ES cells, which are characterized by high levels of PtdIns(3,4,5)P 3 . Ins(1,3,4,5,6)P 5 inhibited cell growth and it was the most active of the inositol polyphosphates tested, confirming our data obtained in cancer cell lines (Figure 5a ). Furthermore, we observed that Ins(1,3,4,5,6)P 5 specifically inhibited phosphorylation of Akt in PTEN À/À ES cells (Figure 5b ) whereas other inositol polyphosphates tested such as Ins(3,4,5,6)P 4 and InsP 6 were inactive. These data indicate that Ins(1,3,4,5,6)P 5 is a specific PtdIns(3,4,5)P 3 competitor and is more active than other inositol polyphosphates.
Ins(1,3,4,5,6)P 5 enhances the proapoptotic effect of cisplatin To determine the conditions for combination treatment, the PI 3-K inhibitor LY294002, Ins(1,3,4,5,6)P 5 and cisplatin were tested in SKOV3 cells. Cisplatin is one of the most effective agents in the treatment of ovarian cancer. To quantify effects on apoptosis, a DAPI assay was performed. As shown in Figure 6a , Ins(1,3,4,5,6)P 5 induced apoptosis to the same extent as cisplatin and LY294002 (data not shown) whereas other inositol polyphosphates were inactive. Interestingly, when Ins(1,3,4,5,6)P 5 was used in combination with cisplatin we observed a more than additive effect that we did not observe when LY294002 and cisplatin (data not shown) were used together. In parallel we determined the effect of LY294002, cisplatin and Ins(1,3,4,5,6)P 5 on Akt phosphorylation in SKOV3 cells. As shown in Figure 6b , LY294002 inhibited serine 473 phosphorylation, similarly to the inhibition obtained when cisplatin or Ins(1,3,4,5,6)P 5 was used. Interestingly when used in combination with cisplatin Ins(1,3,4,5,6)P 5 completely abolished Akt phosphorylation on serine 473.
Ins(1,3,4,5,6)P 5 counteracts the ability of fibronectin to protect cells from undergoing apoptosis It has been shown that adhesion of SCLC cells to extracellular matrix proteins enhances tumorigenicity and confers resistance to chemotherapeutic agents (Sethi À/À ES cells were incubated for 2 h with 50 mM of the indicated inositol polyphosphates or 100 nM wortmannin and phosphorylation of Akt at Ser(473) was assessed in Western blot analysis by using a specific anti-p-Ser(473) antibody. Densitometry analysis was carried out and p-Ser(473)-Akt levels were normalized to the corresponding total amount of Akt. Blot is representative of three independent experiments Figure 6 Ins(1,3,4,5,6)P 5 enhances the apoptotic effect of cisplatin. (a) SKOV3 cells were plated for 24 h and then serum deprived overnight. A measure of 50 mM of different inositol polyphosphates alone or in combination with 50 mM cisplatin were added to cells for 1 h before changing medium to medium containing 50 mM inositol polyphosphate alone. Apoptosis was assessed after 72 h by DAPI staining. (b) SKOV3 cells were plated in six-well plates for 24 h. A measure of 10 mM LY294002, 50 mM Ins(1,3,4,5,6)P 5 alone or in combination with 50 mM cisplatin were added to cells for 1 h. After washing, cells were incubated in medium containing 10 mM LY294002 or 50 mM Ins(1,3,4,5,6)P 5 alone for further 72 h. Phosphorylation of Akt at Ser(473) was assessed in Western blot analysis by using an anti-p-Ser(473) antibody. Total amount of Akt was assessed by using an anti-Akt antibody. Blot is representative of three independent experiments Effect of inositol pentakisphosphate on apoptosis E Piccolo et al Rintoul and Sethi, 2002) . Activation of PI 3-K by integrin seems to be involved in this mechanism of protection. Therefore, we tested the effect of Ins(1,3,4,5,6)P 5 on fibronectin-mediated protection against etoposide-induced apoptosis. As shown in Figure 7a , as expected, cells adherent to fibronectin were markedly protected from apoptosis induced by etoposide; nonspecific adhesion of SCLC cells to poly-L-lysine did not protect cells from chemotherapy-induced apoptosis. Ins(1,3,4,5,6)P 5 induced apoptosis in 56.7% of cells when SCLC were plated on poly-L-lysine (Figure 7b ) whereas this effect was almost completely abrogated in cells plated on fibronectin (21.5% apoptotic cells) indicating that fibronectin protected SCLC from Ins(1,3,4,5,6)P 5 -induced apoptosis as well.
We then tested the effect of combination of Ins(1,3,4,5,6)P 5 with different concentrations of etoposide. When Ins(1,3,4,5,6)P 5 was used in combination with 25 mg/ml etoposide on SCLC cells plated on poly-L-lysine the number of apoptotic cells was similar to that obtained when each single compound was used (Figure 7c , open bars). On the contrary there was an addictive effect on apoptosis when the two compounds were used in combination on SCLC cells plated on fibronectin (Figure 7c , dark bars) and the total number of apoptotic cells in this condition is similar to the number of apoptotic cells obtained with 25 mg/ml etoposide alone on poly-L-lysine. Similar results were obtained when Ins(1,3,4,5,6)P 5 was used in combination with 50 mg/ml etoposide (Figure 7d ). These experiments demonstrate that Ins(1,3,4,5,6)P 5 partially abrogates the fibronectinmediated protection from etoposide-induced apoptosis.
Recent reports have indicated that, in breast cancer cell lines, including MDA-MB-231, a similar integrinmediated protection from drug-induced apoptosis is dependent on activation of the PI 3-K/Akt pathway (Aoudjit and Vuori, 2001 ). Therefore, we tested the effect of Ins(1,3,4,5,6)P 5 on apoptosis induced by paclitaxel in MDA-MB-231 cells. When cells were plated on poly-L-lysine, Ins(1,3,4,5,6)P 5 had no effect on cell apoptosis, in agreement with data shown in Figure 4a . On the contrary, the anticancer drug paclitaxel induced apoptosis in cells plated on poly-L-lysine (50% of cells) (Figure 8 ) whereas this effect was strongly reduced in MDA-MB-231 plated on fibronectin. Interestingly Ins(1,3,4,5,6)P 5 , although inactive when used alone, was able to abolish the fibronectinmediated protection when used in combination with 
Discussion
In the present study, we show that Ins(1,3,4,5,6)P 5 inhibits Akt kinase activity and phosphorylation and induces SKOV3, SCLC and SKBR-3 cell apoptosis.
Among the different inositol polyphosphates tested, Ins(1,3,4,5,6)P 5 is the most active compound. Interestingly, Ins(1,3,4,5,6)P 5 sensitizes breast, ovarian and lung cancer cell lines to anticancer drugs.
These results support an inhibitory activity of Ins(1,3,4,5,6)P 5 on cell proliferation and a proapoptotic action, and the target of this activity seems to be the PI 3-K/Akt signalling pathway. In our previous work (Razzini et al., 2000) we demonstrated that Ins(1,4,5,6)P 4 inhibited cell growth as potently as Ins(1,3,4,5,6)P 5 and this could be in contrast with the weak or lack of effect found on apoptosis. This apparent controversy is explained by the fact that in the present work we have used pure synthetic inositol polyphosphates whereas in our previous observation we used commercial compounds since synthetic inositol polyphosphates were not available. In fact, when tested on apoptosis commercial Ins(1,4,5,6)P 4 possesses an activity comparable to that of Ins(1,3,4,5,6)P 5 (data not shown). The reason for this discrepancy is still unclear. However, we definitively rely more on purity of our synthetic compounds that satisfy the criteria proposed on the use of inositol polyphosphates as discussed below (Shears, 2001 ). The effect of Ins(1,3,4,5,6)P 5 on apoptosis is of particular interest in SKOV3 cells since, in general, ovarian cancer cells present a poor propensity to undergo apoptosis (Vikhanskaya and Broggini, 2002) . Recently, wortmannin and InsP 6 have been found to possess antitumour activity in vitro and in vivo through PI 3-K inhibition, although the general toxicity of wortmannin and the very high concentrations (1-5 mM) of InsP 6 for activity should be taken into account (Shamsuddin, 1999; Ng et al., 2001; Stein, 2001 ). In addition, the lack of selectivity of these compounds, together with the instability of wortmannin and the insolubility of LY294002, means that neither has very promising pharmaceutical potential. One major concern in the use of inositol polyphosphates provided exogenously is the presence of multiple negatively charged phosphate groups and, as a consequence, they are generally considered not to be membrane permeant. Despite the large number of reports indicating that InsP 6 possesses antitumour activity, none of these works provides clear evidence that this compound may enter cells. By contrast, we have already shown that the inositol polyphosphate Ins(1,3,4,5)P 4 may enter SCLC-H69 cells when applied extracellularly (Razzini et al., 2000) . This is very surprising because although several commonly used drugs possess negatively charged groups and are able to enter cells, none of these are polyphosphates. The mechanism by which cell entry occurs is at present unknown. An intriguing hypothesis is that only certain cell types may be permeant to inositol polyphosphates and this may involve specificity in the mechanism of action of inositol polyphosphates. Specific and nonspecific uptake of water-soluble drugs can occur across the plasma membrane through known transporters or by the process of endocytosis or by pinocytosis (Gottesman, 2002) . Recent data show that InsP 6 ionically bound to lipophilic ammonium or polyammonium cations can be delivered across the plasma membrane of erythrocytes indicating that, by complexing the negative charges of the phosphate groups, inositol polyphosphates may be rendered membrane permeant (Vincent et al., 2002) . Another aspect regarding the use of higher inositol polyphosphates is that their activity could reflect some unspecific effect on cell functions due to their peculiar chemical properties (Shears, 2001) . Therefore, a set of criteria, designed to avoid experimental artefacts, has been proposed (Shears, 2001 ) and we have employed these in our evaluation of Ins(1,3,4,5,6)P 5 activity. In particular, the fact that we have used pure Ins(1,3,4,5,6)P 5 , and that other inositol polyphosphates are inactive may rule out any unspecific or toxic effect.
It is known that tumour cell survival reflects a fine balance between hyperproliferative, proapoptotic, and antiapoptotic events. Since tumour cells are more sensitive to proapoptotic factors than normal cells, combination of proapoptotic factors with other anticancer agents may be more effective in the treatment of cancer. In fact, inhibitors of PI 3-K have been shown to increase the ability of conventional anticancer drugs to induce apoptosis (Stein, 2001) . Similarly, in the present study we observed that Ins(1,3,4,5,6)P 5 potentiates the apoptotic effect of anticancer drugs in breast, ovarian and lung cancer cell lines. Therefore, the Figure 8 Ins(1,3,4,5,6)P 5 sensitizes breast cancer cell lines to paclitaxel. MDA-MB-231 cells were seeded into 24-well plates precoated with 100 mg/ml poly-L-lysine or 10 mg/ml fibronectin. After 3 h, cells were incubated with 50 mM Ins(1,3,4,5,6)P 5 for 1 h before adding the indicated concentrations of paclitaxel to each well. After 48 h, apoptosis was detected by acridine orange/ ethidium bromide staining. Values are mean7s.e. of three independent experiments performed in triplicate Effect of inositol pentakisphosphate on apoptosis E Piccolo et al use of Ins(1,3,4,5,6)P 5 in combination with commonly used anticancer drugs may allow us to decrease the concentration of these drugs and their accompanying side effects.
Our attention is focused on the mechanisms of activation of specific downstream effectors of PI 3-K through a PH domain-mediated membrane targeting. We propose that the activation of such proteins may be inhibited by blocking the interaction of PH domains with the lipid product of PI 3-K that is responsible for the translocation and activation of proteins. In particular, ligands of the PH domains have the potential to antagonize the activation of specific proteins by inhibiting their translocation to the plasma membrane (or to any specific membrane compartment). Indeed, as different PH domains possess different binding affinities towards different inositol polyphosphates, this increases the possibility of specifically inhibiting a particular membrane-targeted protein. Thus antagonism of PI 3-K signalling pathways could give us the potential to block a very specific downstream target without interfering with other PI 3-K-mediated signals. In combination with our recent work Razzini et al., 2000) we propose that some inositol polyphosphates, the water-soluble headgroups of phosphoinositides, can provide specific antagonists of these functions. The concentrations of extracellular Ins(1,3,4,5,6)P 5 (20-50 mM) used in this work are higher than the concentrations normally found inside many mammalian cells (5-15 mM) (Szwergold et al., 1987) and therefore compatible with a competitive mechanism.
Recently, the structure of the PH domain of Akt complexed to Ins(1,3,4,5)P 4 has been solved (Thomas et al., 2002) , and this has enabled the key interactions that allow Ins(1,3,4,5)P 4 to bind the Akt PH domain to be defined. It has been shown that the Akt PH domain binds the lipid headgroup in a different mode from that observed in other PtdIns(3,4,5)P 3 -binding PH domains such as those from Btk, Grp1 and DAPP1 (Thomas et al., 2002) . Notably, the 6-OH group of Ins(1,3,4,5)P 4 is completely exposed to solvent, suggesting that the binding site could accommodate the extra phosphate group present in Ins(1,3,4,5,6)P 5 . In contrast, the 2-OH group is orientated towards the binding pocket, which would explain the loss of activity when this position is phosphorylated, as in InsP 6 (Figure 9 ). In addition, the loss of activity in Ins(3,4,5,6)P 4 could be explained by the fact that the 1-phosphate group seems to be very important for recognition (Thomas et al., 2002) . These observations may explain the specificity of Ins(1,3,4,5,6)P 5 binding to Akt PH (Takeuchi et al., 1997) . In fact, a comparison of relative K d values for inositol phosphates binding by PH domains shows that Ins(1,3,4,5,6)P 5 binds to Akt PH with the highest affinity when compared to other inositol polyphosphates whereas other PtdIns(3,4,5)P 3 -binding PH domains such as those from Btk, Grp1 and Gap1 bind Ins(1,3,4,5,6)P 5 with much lower affinity (Kavran et al., 1998) . On the basis of these findings the use of Ins(1,3,4,5,6)P 5 should give a more selective inhibition of the PI 3-K/Akt pathway than the use of PI 3-K inhibitors such as wortmannin and LY294002, and this may explain the differences observed in our data when Ins(1,3,4,5,6)P 5 effect is compared to wortmannin and LY294002. Nevertheless, we cannot exclude the possibility that Ins(1,3,4,5,6)P 5 may possess other intracellular targets. Our subsequent goal will be to develop more selective and potent inhibitors of Akt PH domain binding to phosphoinositides starting from the Ins(1,3,4,5,6)P 5 structure.
The present study has been designed to provide new drugs that act by mimicking known protein structure specificities at the level of their membrane localization through protein--phosphoinositide interactions. The PI 3-K signalling cascade may play a critical role in tumorigenesis, invasion and metastasis. The identification of new functional inhibitors of PI 3-K pathway would provide new tools for the treatment of tumours whose progression is driven by PI 3-K activation or PTEN gene alterations. Since the PTEN gene is deleted or mutated in a wide variety of human cancers the results of this study may have wide clinical implications.
Materials and methods

Materials and plasmids
DMEM, RPMI-1640, FBS and calf serum were obtained from Invitrogen; cisplatin was from SEGIX; etoposide (Vepesid) was from Bristol-Myers, SQUIBB; anti-pSer(473)Akt, and anti-Akt rabbit polyclonal antibodies were from New England Biolabs; ECL was from Amersham Biosciences; [g 32 P]ATP was from Perkin-Elmer. All other biochemicals were of the highest possible purities and were obtained from Sigma.
Ins(1,3,4,5,6)P 5 was synthesized from 4,6-bis-O-(p-methoxybenzyl)-1,3,5-O-methylidyne-myo-inositol (Riley et al., 1998) . Briefly, benzylation followed by removal of acid-labile protecting groups gave 2-O-benzyl myo-inositol, which was subjected to 1H-tetrazole catalysed phosphitylation with bis(benzyloxy)diisopropylaminophosphine, followed by oxidation. The resulting benzyl-protected Ins(1,3,4,5,6)P 5 was deprotected by catalytic hydrogenolysis, and the product was purified to homogeneity by ion-exchange chromatography on Q-Sepharose Fast Flow resin, giving the pure triethylammonium salt of Ins(1,3,4,5,6)P 5 , which was fully characterized by 31 P and 1 H spectroscopy and accurately quantified by Effect of inositol pentakisphosphate on apoptosis E Piccolo et al total phosphate assay. Ins(1,4,5,6)P 4 and Ins(3,4,5,6)P 4 were synthesized in a similar way (Mills et al., 2003) . pCis2-Myr-Akt was a kind gift of Dr MJ Quon (NIH, Bethesda, USA). To obtain a myc-tagged version of myr-Akt, the BglII/EcoRI fragment from pCis2-Myr-Akt was subcloned into an appropriately digested pKMyc vector.
Cell cultures and transfection
SCLC-H69 and SKOV3 cell lines were grown in RPMI 1640 containing 25 mM HEPES; MDA-MB-231, MCF-7 and SKBR-3 were grown in DMEM. All media were supplemented with 10% heat-inactivated FBS. Embryonic stem cell line, PTEN À/À ES, was grown in DMEM supplemented with 15% calf serum (Di Cristofano et al., 1998) . Before all experiments SCLC-H69 cells were incubated in SITA medium for 24 h (RPMI 1640 supplemented with 30 nM selenium, 5 mg/ml insulin, 10 mg/ml transferrin and 0.25% (w/v) BSA). Cell viability was routinely greater than 90%, as judged by trypan blue exclusion. For transfection, SKBR-3 cells were plated at a concentration of 1.5 Â 10 5 cells/well in 24-well plate for 24 h and transfected by using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's protocol. Expression of MyrAkt was assessed in Western blot analysis by using an anti-Akt antibody (for pCis2-Myr-Akt) or by confocal microscopy analysis by using an anti-myc antibody (for pKMyc-Myr-Akt) and a confocal laser-scanning microscope (LSM-510 META -Zeiss) equipped with a Â 40 objective.
Apoptosis assays
SCLC-H69 cells were plated at a concentration of 1 Â 10 5 cells/ well in 48-well plate in SITA medium for 24 h and treated with different concentrations of etoposide or 50 mM inositol polyphosphates for further 24 h. SKOV3 cells were seeded at a concentration of 1 Â 10 5 cells/well in 48-well plates for 24 h, serum deprived overnight and then incubated with different concentrations of Ins(1,3,4,5,6)P 5 or cisplatin for 24 h. For experiments in Figures 7 and 8 , SCLC-H69 or MDA-MB-231 cells were plated onto a 96 well plate precoated overnight at þ 41C with 100 mg/ml poly-L-lysine or 10 mg/ml fibronectin and treated as described in the corresponding figure legends. After treatments, floating cells were collected and adherent cells were harvested by trypsinization and centrifuged at 1000 g for 5 min.
For experiments in SKBR-3-transfected cells, cells were incubated with 50 mM Ins(1,3,4,5,6)P 5 or 100 nM wortmannin 24 h after transfection and apoptosis was evaluated after further 24 h.
Acridine orange/ethidium bromide staining Apoptosis was assessed by adding an acridine orange (100 mg/ml)/ethidium bromide (100 mg/ml) (1/1 v/v) mixture to the cell suspension and the percentage of cells undergoing apoptosis was determined by fluorescent microscopy as described (Duke and Cohen, 1992) .
Annexin V-FITC/propidium iodide staining Apoptosis was evaluated using an 'Annexin V-FITC Apoptosis Detection Kit' (MBL). After centrifugation, cells were resuspended in Annexin V-binding buffer and incubated with 1 mg/ml Annexin V-FITC 1 mg/ml and propidium iodide for 15 min at room temperature. The number of apoptotic cells was determined by flow cytometry analysis using an EPICS ELITE ESP COULTER.
DNA fragmentation SCLC-H69 cells were plated at a concentration of 3 Â 10 6 /well in six-well plates in SITA medium for 24 h and treated with 100 nM wortmannin or 50 mM Ins(1,3,4,5,6)P 5 for further 48 h. Cells were collected by centrifugation (1000 g for 15 min), washed in PBS and then lysed with 0.5 ml of lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 0.5% SDS containing 0.5 mg/ml proteinase K) on ice for 20 min. After centrifugation, DNA was extracted with a mixture phenol : chloroform : isoamilic alcohol (25 : 24 : 1), precipitated with ethanol and resuspended in TE, pH 8.0, containing 5 mg/ml RNase A. After incubation for 1 h at 371C, DNA was analysed by electrophoresis on a 2% agarose.
DAPI staining DAPI staining was performed as described previously (Wang et al., 1997) . In brief, cells were fixed with 4% paraformaldehyde in PBS for 30 min at room temperature. After washing in PBS, DAPI was added for 30 min, before fluorescence microscopy analysis. Apoptotic cells were identified by condensation and fragmentation of nuclei. Percentage of apoptotic cells was calculated as the ratio of apoptotic cells to total cells counted Â 100. A minimum of 400 cells was counted for each treatment.
Western blot analyses
SKOV3, PTEN
À/À ES cells (3 Â 10 4 cells/well in six-well plates) or transfected SKBR-3 were incubated at 371C for 24 h in medium containing 10% FBS. To study the effects of inositol polyphosphates on Akt phosphorylation, 50 mM of the indicated inositol polyphosphates were resuspended in DMEM containing 2% serum and added for 24 h. For combination experiments with chemotherapeutic agent, cells were treated with 10 mM LY294002, 50 mM Ins(1,3,4,5,6)P 5 alone or in combination with 50 mM cisplatin for 1 h. After washing, cells were incubated with LY294002 or Ins(1,3,4,5,6)P 5 for further 72 h.
After treatments, cells were washed once with ice-cold PBS and then lysed in NP-40 lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% NP-40, 2 mM sodium orthovanadate, 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin and 10 mg/ ml pepstatin A) for 20 min at 41C. Insoluble materials were removed by centrifugation (10 000 g for 15 min at 41C) and protein concentration was assessed by the method of Bradford. A measure of 30 mg of total proteins were resuspended in 4 Â Laemmli buffer, boiled for 5 min and separated by SDS/PAGE (8%) before transferring to nitrocellulose membrane. Membranes were then saturated with PBS containing 5% fat free milk for 30 min at room temperature, then incubated with an anti-p-Ser(473)Akt, or an anti-Akt rabbit polyclonal antibody for 2 h in PBS containing 5% fat-free milk. After washing three times for 15 min with PBS containing 0.05% Tween-20, membranes were incubated with a peroxidase-conjugated secondary antibody and bands were revealed by ECL. Densitometry analyses were performed on a Macintosh computer with NIH-Image 1.61/fat and the levels of phosphorylated proteins were normalized to the corresponding total amount of Akt.
Akt kinase activity
SCLC-H69 cells were plated at a concentration of 4 Â 10 6 cells/ well in a six-well plate, and treated with 50 mM of different inositol polyphosphates or 100 nM wortmannin for 30 min. Akt was immunoprecipitated and assayed using 'Akt1/PKB alpha IP-Kinase' kit (Upstate Biotechnology). Cells were lysed in buffer A (50 mM Tris, pH 7.5, 1 mM EDTA, 1 mM EGTA, 0.5 mM sodium orthovanadate, 0.1% 2-mercaptoethanol (v/v), 1% Triton X-100, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 10 mM sodium b-glycerol phosphate, 0.1 mM PMSF, 1 mg/ml aprotinin, pepstatin, leupeptin and 1 mM microcystin), and proteins were quantified using the method of Bradford. Lysates (500 mg) were incubated for 2-3 h with a GST-fusion protein corresponding to residues 1-149 of human a-Akt1/PKBa-PH domain, washed three times with buffer A, and once with kinase buffer (20 mM MOPS, pH 7.2, 25 mM bglycerol phosphate, 5 mM EGTA, 1 mM sodium orthovanadate, 5 mM dithiothreitol). Kinase reaction was performed for 10 min at 301C in kinase buffer supplemented with 100 mM Akt/PKB-specific substrate peptide, 500 mM cold ATP and 1 mCi/ml of [g-32 P]ATP. The phosphorylated substrate was then separated from the residual [g-32 P]ATP by using P81 phosphocellulose paper followed by extensive washes. Radioactivity was then quantified by a scintillation counter.
Alternatively, Akt kinase inhibition was assessed using the Akt kinase assay kit (Upstate Biotechnology, Inc.). Briefly, SKOV3 and SCLC-H69 cells were incubated with 50 mM inositol polyphosphates or 100 nM wortmannin for 2 h in serum-free medium. After treatment cells were washed twice with cold PBS and lysed with lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 mM Na 3 VO 4 , 1mM b-glycerol phosphate, 1 mg/ml leupeptin, 1 mM PMSF). Total cellular proteins were extracted, and Akt was selectively immunoprecipitated by gentle rocking incubation of the sample with anti-Akt antibody at 41C for 3 h. The pellets were washed twice with 500 ml of lysis buffer and twice with 500 ml of kinase buffer. Kinase reaction was performed in 40 ml of kinase buffer containing 200 mM ATP and 1 mg of GSK3-fusion protein for 30 min at 301C. The reaction was stopped by adding 20 ml of SDS loading buffer. Akt kinase activity was determined by Western blot analysis using phospho-GSK3 ab (Ser21/9) antibody. Densitometry analyses were performed on a Macintosh computer with NIH-Image 1.61/fat and the levels of phosphorylated protein were normalized to the corresponding total amount of Akt.
Cell viability assay
Cell viability was assessed by visual cell counting or MTT assay (Mosmann, 1983) . For MTT assay, all cell lines were detached and seeded into 96-well plates at a density of 1 Â 10 4 cells/well in 100 ml DMEM supplemented with 10% fetal calf serum (15% calf serum for PTEN À/À ES cells) for 24 h. To study the effects of Ins(1,3,4,5,6)P 5 on proliferation of different breast cell lines, cells were treated with 50 mM Ins(1,3,4,5,6)P 5 , or 25 mM LY294002 or 100 nM wortmannin for 48 h. To study the effects on PTEN À/À ES cells proliferation, cells were treated with 50 mM of different inositol polyphosphates for 72 h.
After treatments, 100 ml of MTT solution (1 mg/ml) was added to each well and incubated for further 3 h. After removal of MTT solution, 100 ml of DMSO was added to the wells for 30 min and the absorption value at 545 nm was measured using a multiplate reader.
